IN THE surgical management of
|
|
- Elizabeth Grant
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Papillary Thyroid Carcinoma Modified Radical Neck Dissection Improves Prognosis Shiro Noguchi, MD, PhD; Nobuo Murakami, MD; Hiroto Yamashita, MD, PhD; Masakatsu Toda, MD, PhD; Hitoshi Kawamoto, PhD Objective: To ascertain whether modified radical neck dissection offers a survival advantage for some subsets of patients with papillary cancer of the thyroid. Design: A retrospective cohort study of 2966 patients curatively treated at the Noguchi Thyroid Clinic and Hospital Foundation, Oita, Japan, between 1946 and Setting: A center for the treatment of thyroid disease, where about 1400 thyroid operations are performed per year. Patients: Between 1946 and 1991, patients with papillary cancer whose primary tumor was 1 cm or larger and who were curatively treated were studied. Of the 2859 patients, 72.1% underwent modified radical neck dissection, 8.5% underwent partial node excision, and 19.4% underwent no node excision. Results: A univariate analysis revealed a subset of patients who benefited from modified radical neck dissection. A multivariate analysis revealed that sex (P.001), age at the time of the operation (P.001), size of the primary tumor (P.001), extrathyroidal invasion (P.001), and the presence of nodal metastasis (P.01) are significant risk factors. Conclusion: Patients with nodal metastasis, patients in whom the primary tumor invades beyond the thyroid capsule, and women older than 60 years can benefit from modified radical neck dissection. Arch Surg. 1998;133: From the Noguchi Thyroid Clinic and Hospital Foundation (Drs Noguchi, Murakami, Toda, and Kawamoto) and the Department of Pathology, Oita Medical University (Dr Yamashita), Oita, Japan. IN THE surgical management of papillary cancer, controversy exists not only about thyroidectomy but also about the extent of lymph node excision. While there are well-accepted risk factors, such as the patient s age at the time of surgery, the size of the primary tumor, and invasion of the tumor beyond the thyroid capsule, the influence of lymph node metastasis on survival is controversial. In this study, we attempted to address these issues. A randomized trial is believed to be the most reliable and scientific way of comparing 2 therapeutic methods. However, when a randomized trial is not feasible, another approach is to determine whether a group of patients with advanced disease has a better prognosis after undergoing one surgical procedure than another group of patients with less advanced disease who has undergone a less extensive surgical procedure. If so, the more extensive surgical procedure would be justified. We elected to use subtotal thyroidectomy and to perform modified radical neck dissection in most of our patients. Although it is unquestionably established that modified radical neck dissection reduces the recurrence rate, 1,2 its influence on the survival rate still remains unclear. In this article, we report a survival advantage of modified radical neck dissection in some subgroups of patients with papillary thyroid cancer, despite the fact that these patients had more advanced disease. RESULTS PRIMARY TUMOR The mean (±SD) diameter of the primary tumor was 27.1±14.5 mm. The smallest tumor was 10 mm in diameter by definition, and the largest was 150 mm in diameter. The tumor was confined within the thyroid capsule in 912 patients. METASTASIS Gross nodal metastasis was found in 1160 (39.1%) of the patients. In 638 (21.5%) of the patients, nodal metastasis was not examined or counted; in 323 (1% of the patients, metastasis was histologically confirmed not to be present; and in 2005 (67.6%) of the patients, metastasis was histologically confirmed to be present. 276
2 PATIENTS AND METHODS Between 1946 and 1991, 3994 patients seen at the Noguchi Thyroid Clinic and Hospital Foundation, Oita, Japan, had papillary cancer. The following 2 groups of patients were excluded from the study: 124 patients who were not surgically treated or who underwent noncurative surgery (including 17 patients who had pulmonary metastases when they were initially seen and 92 who underwent incomplete resection) and 904 patients whose primary tumor had a maximum diameter of less than 10 mm. Therefore, 2966 patients were included in this study. Information about living patients was obtained by periodic correspondence with the patients themselves, family members, referring physicians, and municipal records. For the deceased patients, the cause of death was confirmed by death certificates or contact with family members and hospitals. The mean follow-up interval in the patients last known to be alive was 15.6 years. Twelve (%) of the patients were unavailable for follow-up, 170 died of thyroid cancer, and 333 died of unrelated causes. The cause-specific survival rates were calculated according to the Kaplan-Meier method. Risk factor analysis was performed using the Cox proportional hazards regression model. 2 Analysis was applied for comparisons between 2 groups with a similar distribution, and the Wilcoxon rank sum test Kruskal-Wallis test was applied for groups with an irregular distribution. TYPES OF THYROIDECTOMY AND LYMPH NODE EXCISION Total thyroidectomy was performed in 75 (2.5%) of the patients; subtotal thyroidectomy, 1233 (41.6%) of the patients; lobectomy, 1217 (41.0%) of the patients; and partial lobectomy, 441 (14.9%) of the patients. Our routine method of subtotal thyroidectomy is to leave behind 1 or2goftheupper pole of the unaffected lobe, with the parathyroid gland left in situ. When intraglandular dissemination is present on the contralateral upper pole, we try to leave behind 1.0 or 1.5 g of the upper pole of any side that looks normal. Lobectomy is almost always accompanied by isthmectomy. A special explanation is required regarding patients who underwent partial lobectomy. Of the 441 patients, 71 had concomitant benign disease; of these 71 patients, 66 underwent the operation for that reason. The remaining patients had a small tumor. Of the 441 patients, 78 underwent modified radical neck dissection, 69 underwent central compartment node dissection, and the remaining 294 underwent no node excision. This procedure was mostly performed between 1970 and The modified radical neck dissection encompassed dissection of the fat and lymph node tissues around the trachea (central compartment) and those around the jugular vein extending from the common carotid artery up to the bifurcation, superior to the bifurcation the Table 1. Lymph Node Excision in Relation to Thyroidectomy* Type of Procedure Total thyroidectomy (n = 75) Subtotal thyroidectomy (n = 1233) Lobectomy (n = 1217) Partial lobectomy (n = 441) Modified Radical Neck Dissection Partial Node Excision internal carotid artery to the trapezius muscle, and from the subclavian vein to the hypoglosseal nerve (lateral compartment). Patients who underwent modified radical neck dissection had macroscopic metastasis, invasion of the primary tumor to surrounding tissue, or a preoperative diagnosis of cancer. Further analysis was performed by dividing the patients into 2 groups, those treated with modified radical neck dissection and those not treated with modified radical neck dissection, because of the few patients in the central compartment excision group. Table 1 shows the number and percentage of patients treated with each type of thyroidectomy and lymph node excision. Patients who did not undergo this dissection had no macroscopic metastasis and minimal or no invasion to surrounding tissue. The differences between the 2 groups are summarized in Table 2. INVASION OR ADHESION No Node Excision 68 (9) 6 (8.0) 1 (1.3) 1022 (82.9) 90 (7.3) 121 (9.8) 971 (79.8) 87 (7.1) 159 (13.1) 78 (17.7) 69 (15.6) 294 (66.7) *All data are given as the number (percentage) of patients who underwent each type of procedure. Table 2. Characteristics of Underwent Modified Radical Neck Dissection (MRND) Compared With Did Not * Characteristics Underwent MRND (n = 2139) Patients Who Did Not (n = 827) Preoperative diagnosis of cancer 1839 (86.0) 292 (35.3) Extrathyroidal invasion 814 (38.1) 98 (11.8) Adhesion Recurrent nerve 628 (29.4) 35 (4.2) To the esophagus 354 (16.5) 22 (2.7) To the larynx 116 (5.4) 8 (1.0) To the jugular vein 255 (11.9) 23 (2.8) Mean diameter, mm *All data are given as the number (percentage) of patients in each group. Except for mean diameter ( P.22), all differences between groups were significant ( P.001). In this type of retrospective study, adhesion and invasion of the primary tumor to the surrounding tissues were hard to differentiate strictly; therefore, they were grouped together. The incidence of invasion or adhesion of the primary tumor to surrounding tissues increased with age 277
3 Did Not Did Not Figure 1. Modified radical neck dissection (MRND) improves the cause-specific survival rate in patients whose primary tumor had extrathyroidal invasion (n=912, 3% of the total) ( P.02, log-rank test, and P.01, Wilcoxon rank sum test). (P.001). The incidence of nodal metastasis in male and female patients was 92.1% and 85.5%, respectively. The difference was significant (P.009). The patients in whom there was invasion or adhesion of the primary tumor to surrounding tissue and who experienced gross nodal involvement had a better survival rate after a modified radical neck dissection was performed, as shown in Figure 1 and Figure 2, respectively. Although the overall survival rates in the group that underwent modified radical neck dissection and in the group that did not undergo modified radical neck dissection were not statistically different, among patients with any metastases, the group that underwent modified radical neck dissection had a survival advantage (Figure 3). AGE Patients were classified into 4 age groups: younger than 20 years, between 20 and 50 years, between 51 and 60 years, and older than 60 years. Older age was a significant (P.001) risk factor. In women older than 60 years, who composed 17.7% of the patients, modified radical neck dissection conferred a significant (P.02, logrank test, and P.007, Wilcoxon rank sum test) survival advantage regardless of the risk factors (Figure 4). The 10- and 20-year cause-specific survival rates for the group that underwent modified radical neck dissection (n=373) were 92.4% and 73.2% compared with 8% and 56.7%, respectively, for the group that did not undergo modified radical neck dissection (n=130). RECURRENCE FROM REMNANT THYROID Recurrence in the remnant thyroid tissue was observed in 97 (3.3%) of the patients. The contralateral lobe was affected in 74 patients, the ipsilateral thyroid bed was affected in 22 patients, and the bilateral lobes were affected Figure 2. Modified radical neck dissection (MRND) improves the cause-specific survival rate in patients who had gross nodal metastasis (n=1157, 39.0% of the total) ( P.009, log-rank test, and P.005, Wilcoxon rank sum test). in 1 patient. Among these patients, 83 were successfully treated by a second operation and 1 survived with disease; of the remaining 13 (%) of the patients, 11 (7%) died of distant metastasis and 2 (0.07%) died of local disease. MULTIVARIATE ANALYSIS OF RISK FACTORS The significant risk factors were sex (P.001), age at the time of the operation (P.001), maximum diameter of the primary tumor (P.001), extrathyroidal invasion (P.001), and presence of metastasis regardless of the size of the tumor (P.04). COMMENT Since 1970, when we first noted the extremely high incidence of nodal metastases in patients with papillary cancer of the thyroid, we have advocated modified radical neck dissection for these patients. 3,4 Recently, Simon and Goretzki 1 noticed a high nodal recurrence rate and suggested the usefulness of a modified radical neck dissection. Scheumann et al 2 reported improvement of the recurrence rate and the survival rate after a modified radical neck dissection; however, the indication criteria were not clarified. Although many had failed to find improvement of the survival rate after modified radical neck dissection, 5-8 we were able to demonstrate the beneficial effect of modified radical neck dissection on survival in some subsets of female patients with papillary cancer of the thyroid by univariate and multivariate analyses. There are several possible reasons why previous studies have failed to demonstrate any benefit of modified radical neck dissection. This form of surgery has often been applied exclusively for advanced disease: the percentage of patients with papillary cancer of the thyroid who underwent radical or modified radical neck dissection ranged from 12.3% to 30.0% in institutions in which the procedure 278
4 Did Not Did Not Figure 3. Modified radical neck dissection (MRND) improves the cause-specific survival rate in patients who had nodal metastasis of any size (n=2005, 67.6% of the total) ( P.04, log-rank test, and P.007, Wilcoxon rank sum test) Figure 4. Modified radical neck dissection (MRND) improves the cause-specific survival rate in female patients older than 60 years, regardless of other risk factors (n=468, 15.8% of the total) ( P.02, log-rank test, and P.007, Wilcoxon rank sum test). is reserved only for patients with gross nodal metastasis Moreover, because recurrence in cervical nodes can be treated easily and successfully by a second surgery, such recurrence may not have affected the survival in many instances. 5,6,13-15 Because of the indolent nature of papillary cancer, the probability of differences of diseasespecific survival rates among groups given different treatments is small and, therefore, an analysis of many cases is necessary before any significant difference will emerge. 16 Finally, not all patients benefit from modified radical neck dissection, and there are no criteria for identifying patients who are, and who are not, likely to benefit. Recent advances of statistical models and computer technology enabled us to analyze many patients with multiple risk factors. 2,9,17-20 With the use of multivariate analysis, the age of the patients at the time of the operation, the size of the primary tumor, the presence of gross nodal involvement, and the presence of remote metastasis when they were specifically mentioned have been agreed on as the risk factors in the literature we examined. 13,17,21-23 However, a scoring system or a classification of patients based on prognosis, inclusive of nodal metastasis, is only given in the article that we previously published. 20 Aside from these rather sophisticated mathematical methods of analysis, Cady et al 24 made a simple and practical rating system named AMES, which is essentially based on the age of the patient, the presence of remote metastasis, the extension of the primary tumor beyond the thyroid capsule, and the size of the primary tumor. They further developed the concept of risk group definition. With the use of multivariate analysis, as well as histological grading, Hay et al 25 proposed a new scoring system inclusive of histological grading, known as AGES, which denotes age of the patient, histological grade of the tumor, extension beyond the thyroid capsule, and size of the primary tumor. They further developed and improved their scoring system by excluding histological grading and including completeness of the resection, invasion of the primary tumor to surrounding tissues, and size of the primary tumor. 25 None of these scoring systems but ours singularly ignored nodal involvement, despite the fact that multivariate analysis clearly proved that gross nodal involvement is one of the risk factors. Routine or frequent use of radioactive iodine with the objective of ablating microscopic cancer foci is recommended by those who advocate total thyroidectomy. 5,6,26-28 Those who do not perform total thyroidectomy routinely use radioactive iodine in selected patients. 29,30 We employ radioactive iodine only when remote metastasis is evident and when the metastasis can accumulate radioactive iodine, not only because of the strict regulation of radioisotopes in Japan but because we also believe that calcitonin secretion must be preserved. In our series, male patients had a higher incidence of nodal metastasis. This observation agreed with the observations of Tisell et al, 12 Tscholl and Hedinger, 31 and Ahuja et al. 32 Although we are aware that total thyroidectomy is a safe procedure when it is performed by skilled and wellexperienced surgeons, we still try to avoid total thyroidectomy for the simple reason that it does not seem to improve the survival rate. Because of this policy, we paid particular attention to recurrence at the remnant thyroid. Of the 2966 patients who we observed on average for 15.6 years, only 13 (%) died of causes related to recurrence in the remnant thyroid or thyroid bed; among these patients, only 2 (0.07%) died with neck disease. Many other researchers are also unable to find any survival advantage of total thyroidectomy. 7,14,36-40 Samaan et al 26 indicated that total thyroidectomy was associated with a longer disease-free interval and less recurrence. However, in their more recent article, 41 a higher survival rate was reported. 42 We wonder whether the total thyroidec- 279
5 tomies were performed by more experienced surgeons compared with the less extensive thyroidectomies. The bone mineral content is reduced after total thyroidectomy. 42 Therefore, if there is no benefit associated with total thyroidectomy in appropriately selected patients, then the increased risk of osteoporosis should be avoided. Most researchers agree that older patients with differentiated thyroid cancer have a relatively poorer prognosis. In the men and women in our study, age was one of the most important risk factors. Women older than 60 years accrue a survival advantage when they undergo modified radical neck dissection, regardless of other risk factors. Univariate and multivariate analyses of modified radical neck dissection indicated a survival advantage in older women. However, women younger than 55 years, those without gross metastasis, and those without extrathyroidal invasion seemed to derive no benefit from this procedure. The size of the primary tumor is also recognized as one of the risk factors by many researchers. In this study, the size was a significant risk factor per multivariate analysis. Invasion of the primary tumor beyond the thyroid capsule is one of the risk factors reported by others. 5,6,14,15,39,43 The incidence of invasion of the primary tumor to surrounding tissues progressively increases with age. The influence of age on prognosis is not explained by invasion alone; inversely, the invasiveness of the primary tumor might be under the influence of a factor or factors possibly related to age. Thus, we found that modified radical neck dissection improved the outcome in some subsets of patients with papillary cancer of the thyroid: specifically, those in whom gross nodal metastasis was noticed before or during surgery, those in whom the primary tumor invaded beyond the thyroid capsule, and those who were women older than 60 years. Presented in part at the 30th World Congress of the International College of Surgeons, Kyoto, Japan, November 26, Reprints: Shiro Noguchi, MD, PhD, the Noguchi Thyroid Clinic and Hospital Foundation, Noguchi Nakamachi 6-33, Beppu, Oita 874, Japan. REFERENCES 1. Simon D, Goretzki PE. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg. 1996;20: Scheumann GSW, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastasis in papillary thyroid cancer. World J Surg. 1994;18: Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid, I: developing pattern of metastasis. Cancer. 1970;26: Noguchi S, Murakami N. The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg Clin North Am. 1987;67: Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70: DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71: McConahey WM, Hay ID, Woolner LB, et al. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986;61: Cunningham MP, Duda RB, Recant W, et al. Survival discriminants for differentiated thyroid cancer. Am J Surg. 1990;160: Salvensen H, Njolstad PR, Akslen LA, et al. Thyroid carcinoma: results from surgical treatment in 211 consecutive patients. Eur J Surg. 1991;157: McHenry CR. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg. 1991;162: Proye C, Carnaille B, Vix M, et al. Récidives ganglionaires des cancers thyroïdiens opéré: de l inutilité du curage ganglionaire de principe (carcinomes medullaires ecclus). Chirurgie. 1992;118: Tisell L-E, Nilsson B, Mölne J, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg. 1996;20: Simpson WJ, McKinney SE, Carruthers JS, et al. Papillary and follicular thyroid cancer: prognostic factors in 1578 patients. Am J Med. 1987;83: Rossi RD, Cady B, Silverman ML, et al. Current results of conservative surgery for differentiated thyroid carcinoma. World J Surg. 1986;10: Vickery AJ, Wang CA, Walker AM. Treatment of intrathyroidal papillary carcinoma of the thyroid. Cancer. 1987;60: Udelsman R, Lakatos E, Landenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg. 1996;20: Tubiana M, Schlumberger M, Rougier P. Long-term results and prognostic factors in patients with differentiated thyroid cancer. Cancer. 1985;55: Bacourt F, Asselain B, Savoie JC, et al. Multifactorial study of prognostic factors in differentiated thyroid carcinoma and a re-evaluation of importance of age. Br J Surg. 1986;73: Kerr DJ, Burt AD, Boyle P, MacFarlane GJ, Storer AM, Brewin TB. Prognostic factors in thyroid tumours. Br J Cancer. 1986;54: Noguchi S, Murakami N, Kawamoto H. Classification of papillary cancer of the thyroid based on prognosis. World J Surg. 1994;18: Bacourt F, Asselain B, Svoiet JC, et al. Multifactorial study of prognostic factors in differentiated thyroid carcinoma and reevaluation of importance of age. Br J Surg. 1986;73: Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid: a clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer. 1985;55: Sellers M, Beeken S, Blankenship A, et al. Prognostic significance of cervical lymph node metastasis in differentiated thyroid cancer. Am J Surg. 1992;164: Cady B, Sedgwick CE, Meissner WA, Wool MS, Salzman FA, Werber J. Risk factor analysis in differentiated thyroid carcinoma. Cancer. 1979;43: Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: developing a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through Surgery. 1993;114: Samaan NA, Maheshwari YK, Nader S, et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab. 1983; 56: Beenken S, Guillamondegui O, Shallenberger R, et al. Prognostic factors in patients dying of well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg. 1989;115: Frankenthaler RA, Sellin RV, Cangir A, et al. Lymph node metastasis from papillaryfollicular thyroid carcinoma in young patients. Am J Surg. 1990;160: Rosen IB, Maitland A. Changing the operative strategy for thyroid cancer by node sampling. Am J Surg. 1983;146: Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104: Tscholl DJ, Hedinger CE. Papillary thyroid carcinomas: morphology and prognosis. Virchows Arch [Pathol Anat]. 1982;396: Ahuja S, Ernst H, Lenz K. Papillary thyroid carcinoma: occurrence and types of lymph node metastases. J Endocrinol Invest. 1991;14: Attie NJ, Khafif AR, Steckler MR. Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg. 1971;122: Clark OH. Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg. 1982;196: Reeve TS, Delbridge L, Crummer P. Total thyroidectomy in the management of differentiated thyroid cancer: a review of 258 cases. AustNZJSurg. 1986;56: Schroder DM, Chambors A, France CJ. Operative strategy for thyroid cancer: is total thyroidectomy worth the price. Cancer. 1986;58: Shah JP, Loree TR, Dharker D, et al. Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis. Am J Surg. 1993; 166: Hoie J, Stenwig AE, Brennhovd IO. Surgery in papillary thyroid carcinoma: a review of 730 patients. J Surg Oncol. 1988;37: Tourniaire J, Bernard AM, Adeleine P, et al. Les éléments du prognostic des cancers thyrïdiens différenciés: 536 observations. Ann Endocrinol (Paris). 1989;50: Starnes HF, Brooks DC, Pinkus GS, et al. Surgery for thyroid carcinoma. Cancer. 1985;55: Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75: McDermott MT, Kidd GS, Blue P, et al. Reduced bone mineral content in totally thyroidectomized patients: possible effect of calcitonin deficiency. J Clin Endocrinol Metab. 1983;56: Coburn MC, Wanebo H. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg. 1992;164:
ORIGINAL ARTICLE. Indications for Bilateral Modified Radical Neck Dissection in Patients With Papillary Carcinoma of the Thyroid
ORIGINAL ARTICLE Indications for Bilateral Modified Radical Neck Dissection in Patients With Papillary Carcinoma of the Thyroid Akira Ohshima, MD, PhD; Hiroyuki Yamashita, MD, PhD; Shiro Noguchi, MD, PhD;
More informationORIGINAL ARTICLE. Changing Trends and Prognoses for Patients With Papillary Thyroid Cancer
ORIGINAL ARTICLE Changing Trends and Prognoses for Patients With Papillary Thyroid Cancer Hiroyuki Yamashita, MD, PhD; Shiro Noguchi, MD, PhD; Hiroto Yamashita, MD, PhD; Nobuo Murakami, MD; Shin Watanabe,
More information유두상갑상선암종에서경부림프절전이의양상및치료
KISEP Head and Neck Korean J Otolaryngol 2005;48:506- 유두상갑상선암종에서경부림프절전이의양상및치료 태경 전성하 이현창 김경래 이형석 박용수 2 안유헌 2 김태화 2 Pattern and Treatment of Papillary Thyroid Carcinoma with Cervical Lymph Node Metastasis
More informationPAPER. Predicting Outcome and Directing Therapy for Papillary Thyroid Carcinoma
PAPER Predicting Outcome and Directing Therapy for Papillary Thyroid Carcinoma Sendia Kim, MD; John P. Wei, MD; Joshua M. Braveman, MD; David M. Brams, MD Hypothesis: The prognosis of papillary thyroid
More informationORIGINAL ARTICLE. Management and Outcome of Recurrent Well-Differentiated Thyroid Carcinoma
ORIGINAL ARTICLE Management and Outcome of Recurrent Well-Differentiated Thyroid Carcinoma Carsten E. Palme, MBBS, FRACS; Zeeshan Waseem, BA; S. Naweed Raza, BSc; Spiro Eski, MD; Paul Walfish, MD, FRCPC;
More informationSARDA AND OTHERS No. of patients (%) Figure 1. Age distribution. Papillary Follicular < > 60 Age at chagnos
Asian Journal of Surgery Excerpta Medica Asia Ltd Prognostic Factors for Well-Differentiated Thyroid Cancer in an Endemic Area A.K. Sarda, Shweta Aggarwal, Durgatosh Pandey, Gagan Gautam, Department of
More informationPrognostic Factors for Well Differentiated Thyroid Cancer in an Endemic Area
Prognostic Factors for Well Differentiated Thyroid Cancer in an Endemic Area A retrospective analysis of 215 differentiated thyroid cancers was undertaken to identify the various prognostic variables.
More informationDifferentiated Thyroid Carcinoma: The Impact of Initial Surgical Therapy
CLINICAL STUDY Differentiated Thyroid Carcinoma: The Impact of Initial Surgical Therapy Dr. Gamal A. Khairy FRCS, FBS, MS Associate Professor of Surgery and Consultant Surgeon College of Medicine, King
More information10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary
Surgery for Well-differentiated Thyroid Carcinoma- The Primary Head and Neck Endocrine Surgery Department of Otolaryngology-Head and Neck Surgery, UCSF October 24-25, 2008 Robert A. Sofferman, MD Professor
More informationGerard M. Doherty, MD
Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationT here are four parathyroid glands, which are located
245 ORIGINAL ARTICLE Parathyroid invasion, nodal recurrence, and lung metastasis by papillary carcinoma of the thyroid K Kakudo, W Tang, Y Ito, Y Nakamura, H Yasuoka, S Morita, A Miyauchi... See end of
More informationThyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES
AJC 7/14/06 1:19 PM Page 67 Thyroid C73.9 Thyroid gland SUMMARY OF CHANGES Tumor staging (T) has been revised and the categories redefined. T4 is now divided into T4a and T4b. Nodal staging (N) has been
More informationReoperative central neck surgery
Reoperative central neck surgery R. Pandev, I. Tersiev, M. Belitova, A. Kouizi, D. Damyanov University Clinic of Surgery, Section Endocrine Surgery University Hospital Queen Johanna ISUL Medical University
More informationPrognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications
Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications Arja Jukkola, Risto Bloigu 1, Tapani Ebeling 2, Pasi Salmela 2 and Guillermo Blanco Department
More informationUltrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer
Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,
More informationReview Article Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma
SAGE-Hindawi Access to Research Thyroid Research Volume 2011, Article ID 634170, 6 pages doi:10.4061/2011/634170 Review Article Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma Yasuhiro
More informationClinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma
524 Clinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma A Population-Based, Nested Case Control Study Catharina Ihre Lundgren, M.D. 1,2 Per Hall, M.D., Ph.D. 1 Paul W. Dickman,
More informationTitle. CitationInternational Cancer Conference Journal, 4(1): Issue Date Doc URL. Rights. Type. File Information
Title Lymph node metastasis in the suprasternal space from Homma, Akihiro; Hatakeyama, Hiromitsu; Mizumachi, Ta Author(s) Tomohiro; Fukuda, Satoshi CitationInternational Cancer Conference Journal, 4(1):
More informationThyroid. At-A-Glance. Papillary or follicular (differentiated) UNDER 45 YEARS Stage I Any T Any N M0 Stage II Any T Any N M1
8 Thyroid At-A-Glance S U M M A R Y O F C H A N G E S Tumor staging (T1) has been subdivided into T1a ( 1 cm) and T1b ( 1 2 cm) limited to thyroid The descriptors to subdivide T categories have been changed
More informationA variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study
ORIGINAL ARTICLE A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study Joon-Hyop Lee, MD, Yoo Seung Chung, MD, PhD,* Young Don Lee, MD, PhD
More informationSurgical Treatment for Papillary Thyroid Carcinoma in Japan: Differences from Other Countries
REVIEW ARTICLE J Korean Thyroid Assoc Vol. 4, No. 2, November 2011 Surgical Treatment for Papillary Thyroid Carcinoma in Japan: Differences from Other Countries Yasuhiro Ito, MD and Akira Miyauchi, MD
More information4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.
Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:
More informationInitial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits?
Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits? Julie Ann Sosa, MD MA FACS Professor of Surgery and Medicine Chief, Section of Endocrine
More informationORIGINAL ARTICLE. The Importance of Central Compartment Elective Lymph Node Excision in the Staging and Treatment of Papillary Thyroid Cancer
ORIGINAL ARTICLE The Importance of Central Compartment Elective Lymph Node Excision in the Staging and Treatment of Papillary Thyroid Cancer Maisie Shindo, MD; James C. Wu, MD; Eunice E. Park, MPH; Frances
More informationTHYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine
THYROID CANCER IN CHILDREN Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine Thyroid nodules Rare Female predominance 4-fold as likely to be malignant Hx Radiation exposure?
More informationThyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.
Thyroid Gland Protocol applies to all malignant tumors of the thyroid gland, except lymphomas. Procedures Cytology (No Accompanying Checklist) Partial Thyroidectomy Total Thyroidectomy With/Without Lymph
More informationORIGINAL ARTICLE. of thyroid cancer will be diagnosed in 1997, 1 and the overwhelming majority
ORIGINAL ARTICLE Sentinel Lymphadenectomy in Thyroid Malignant Neoplasms Pond R. Kelemen, MD; Andre J. Van Herle, MD; Armando E. Giuliano, MD Background:Lymphnodemetastasesforwell-differentiated thyroid
More informationIncidental versus clinically evident thyroid cancer: A 5-year follow-up study
ORIGINAL ARTICLE Incidental versus clinically evident : A 5-year follow-up study Michele N. Minuto, MD, PhD, 1 * Mario Miccoli, DStat, 2 David Viola, MD, 3 Clara Ugolini, MD, PhD, 1 Riccardo Giannini,
More informationDifferentiated Thyroid Cancer: Initial Management
Page 1 ATA HOME GIVE ONLINE ABOUT THE ATA JOIN THE ATA MEMBER SIGN-IN INFORMATION FOR PATIENTS FIND A THYROID SPECIALIST Home Management Guidelines for Patients with Thyroid Nodules and Differentiated
More informationPre-operative Ultrasound of Lymph Nodes in Thyroid Cancer
Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer AACE - Advances in Medical and Surgical Management of Thyroid Cancer - 2018 Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationValidity of risk group definition in
Validity of risk group definition in differentiated thyroid carcinoma J M G\l=o'\mez,N G\l=o'\mez,M Sah\l=u'\n, A Rafecas, C Villabona and J Soler Services of Endocrinology and Surgery, Ciudad Sanitaria
More informationOverview. Extraglandular Thyroid Lymphatics. Management of the Lateral Neck in Well-Differentiated Thyroid Carcinoma. David W. Eisele, M.D., F.A.C.S.
Management of the Lateral Neck in Well-Differentiated Thyroid Carcinoma David W. Eisele, M.D., F.A.C.S. Head and Neck Surgery and Oncology U.C.S.F. Comprehensive Cancer Center University of California,
More informationCAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release
CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release 2 REVISION HISTORY Date Author / Editor Comments 5/19/2014 Jaleh Mirza Created the document 8/12/2014 Samantha Spencer/Jaleh
More informationORIGINAL ARTICLE. Influence of Previous Radiation Exposure on Pathologic Features and Clinical Outcome in Patients With Thyroid Cancer
ORIGINAL ARTICLE Influence of Previous Radiation Exposure on Pathologic Features and Clinical Outcome in Patients With Thyroid Cancer Raewyn M. Seaberg, MD, PhD; Spiro Eski, MD; Jeremy L. Freeman, MD,
More informationPapillary Thyroid Microcarcinoma Presenting as Horner s Syndrome: A Novel Clinical Presentation
Case Report American Journal of Cancer Case Reports http://ivyunion.org/index.php/ajccr/ Page 1 of 6 Papillary Thyroid Microcarcinoma Presenting as Horner s Syndrome: A Novel Clinical Presentation Ammara
More informationAssociation between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study
ONCOLOGY LETTERS 10: 1749-1754, 2015 Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study SHANGTONG LEI 1, ZIHAI
More informationOncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J.
UvA-DARE (Digital Academic Repository) Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J. Link to publication Citation for published version (APA): Nixon, I. J. (2013).
More informationResearch Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients
yroid Research, Article ID 818134, 4 pages http://dx.doi.org/10.1155/2014/818134 Research Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients
More informationORIGINAL ARTICLE. Incidental Parathyroidectomy During Thyroid Surgery Does Not Cause Transient Symptomatic Hypocalcemia
ORIGINAL ARTICLE Incidental Parathyroidectomy During Thyroid Surgery Does Not Cause Transient Symptomatic Hypocalcemia Aaron R. Sasson, MD; James F. Pingpank, Jr, MD; R. Wesley Wetherington, MD; Alexandra
More informationCarcinoma of thyroid - clinical presentation and outcome
Med. J. Malaysia Vol. 46 No. 3 September 1991 Carcinoma of thyroid - clinical presentation and outcome K. Sothy, MBBS M. Mafauzy, MBBS, MRCP, M.Med. Sci. W.B. Wan Mohamad, MD, MRCP B.E. Mustaffa, MBBS,
More informationRole of Radio-Iodine Ablation According to Risk Stratification in Well Differentiated Thyroid Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 13, No. 1, March: 6369, 2001 Role of RadioIodine Ablation According to Risk Stratification in Well Differentiated Thyroid Cancer HOSNA MOUSTAFA, M.D.*; SHEREEN
More informationDr J K Jekel Dept. Surgery University of Pretoria
Dr J K Jekel Dept. Surgery University of Pretoria No Maybe ( T`s and C`s apply ) 1. Total thyroidectomy 2. Neck dissection only if nodes are involved 3. Ablative dose or doses of Radioactive Iodine 4.
More information40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016
Outcomes from the diagnostic approach of thyroid lesions using US-FNA and LBC in clinical practice Emmanouel Mastorakis MD PhD Cytopathologist Director in Cytopathology Laboratory Regional General Hospital
More informationORIGINAL ARTICLE. Follicular Variant of Papillary Thyroid Carcinoma
Follicular Variant of Papillary Thyroid Carcinoma A Long-term Follow-up ORIGINAL ARTICLE Christian Passler, MD; Gerhard Prager, MD; Christian Scheuba, MD; Barbara E. Niederle, MD; Klaus Kaserer, MD; Georg
More informationBiomedical Research 2017; 28 (21): ISSN X
Biomedical Research 2017; 28 (21): 9497-9501 ISSN 0970-938X www.biomedres.info Analysis of relevant risk factor and recurrence prediction model construction of thyroid cancer after surgery. Shuai Lin 1#,
More informationDynamic Risk Stratification:
Dynamic Risk Stratification: Using Risk Estimates to Guide Initial Management R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine
More informationAvi Khafif, MD, Rami Ben-Yosef, MD, Avrum Abergel, MD, Ada Kesler, MD, Roee Landsberg, MD, Dan M. Fliss, MD
ORIGINAL ARTICLE ELECTIVE PARATRACHEAL NECK DISSECTION FOR LATERAL METASTASES FROM PAPILLARY CARCINOMA OF THE THYROID: IS IT INDICATED? Avi Khafif, MD, Rami Ben-Yosef, MD, Avrum Abergel, MD, Ada Kesler,
More informationWTC 2013 Panel Discussion: Minimal disease
WTC 2013 Panel Discussion: Minimal disease Susan J. Mandel MD MPH Panelists Ken Ain Yasuhiro Ito Stephanie Lee Erich Sturgis Mark Urken Faculty/Presenter Disclosure Relationships with commercial interests
More informationManagement guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007
Management guideline for patients with differentiated thyroid Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Incidence (Srinagarind Hospital, 2005, both sex) Site (all) cases % 1. Liver 1178 27 2. Lung
More informationResearch Article A Study on Central Lymph Node Metastasis in 543 cn0 Papillary Thyroid Carcinoma Patients
International Endocrinology Volume 2016, Article ID 1878194, 5 pages http://dx.doi.org/10.1155/2016/1878194 Research Article A Study on Central Lymph Node Metastasis in 543 cn0 Papillary Thyroid Carcinoma
More informationChapter 14: Thyroid Cancer
The American Academy of Otolaryngology Head and Neck Surgery Foundation (AAO-HNSF) Presents... Chapter 14: Thyroid Cancer Daiichi Pharmaceutical Corporation, marketers and distributors of FLOXIN Otic (ofloxacin
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationOriginal Article Multicentric papillary thyroid carcinoma: a clinical analysis of 221 patients
Int J Clin Exp Pathol 2016;9(5):5680-5686 www.ijcep.com /ISSN:1936-2625/IJCEP0020606 Original Article Multicentric papillary thyroid carcinoma: a clinical analysis of 221 patients Xiao-Jun Zhang 1*, Ting
More informationEvaluation of thyroid isthmusectomy as a potential treatment for papillary thyroid carcinoma limited to the isthmus: A clinical study of 73 patients
ORIGINAL ARTICLE Evaluation of thyroid isthmusectomy as a potential treatment for papillary thyroid carcinoma limited to the isthmus: A clinical study of 73 patients Jianbiao Wang, MM, 1 Haili Sun, BM,
More informationOncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J.
UvA-DARE (Digital Academic Repository) Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J. Link to publication Citation for published version (APA): Nixon, I. J. (2013).
More informationPrognostic value of the 8 th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan
2018, 65 (6), 621-627 ORIGINAL Prognostic value of the 8 th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan Yasuhiro Ito 1), Akira
More informationAdjuvant therapy for thyroid cancer
Carcinoma of the thyroid Adjuvant therapy for thyroid cancer John Hay Department of Radiation Oncology Vancouver Cancer Centre Department of Surgery UBC 1% of all new malignancies 0.5% in men 1.5% in women
More informationELIZABETH CEDARS DR. KOREY HOOD Available September 29
ELIZABETH CEDARS DR. KOREY HOOD Available September 29 Title and Investigators Optimizing Surgical Management of Thyroid Cancer: Using Surgeon-performed Ultrasound to Predict Extrathyroidal Extension of
More informationTumor Sprouting in Papillary Thyroid Carcinoma Is Correlated with Lymph Node Metastasis and Recurrence
The Korean Journal of Pathology 2014; 48: 117-125 ORIGINAL ARTICLE Tumor Sprouting in Papillary Thyroid Carcinoma Is Correlated with Lymph Node Metastasis and Recurrence Eunjung Lee Wonkyung Jung Jeong-Soo
More informationTitle:Number of tumor foci predicts prognosis in papillary thyroid cancer
Author's response to reviews Title:Number of tumor foci predicts prognosis in papillary thyroid cancer Authors: Qing-hai Ji (quningfudan@hotmail.com) Ning Qu (jonathan_qn@163.com) Ling Zhang (zhangling@163.com)
More informationCitation Auris, nasus, larynx (2011), 38(3):
TitleManagement of metastasis to the thy Author(s) Ishikawa, Masaaki; Hirano, Shigeru; Citation Auris, nasus, larynx (2011), 38(3): Issue Date 2011-06 URL http://hdl.handle.net/2433/139807 Right 2010 Elsevier
More informationAdvances in the management of thyroid cancer
International Journal of Surgery (2005) 3, 213e220 www.int-journal-surgery.com REVIEW Advances in the management of thyroid cancer Ashok R. Shaha* Memorial Sloan-Kettering Cancer Center, 1275 York Avenue,
More informationManagement of Recurrent Thyroid Cancer
Management of Recurrent Thyroid Cancer Eric Genden, MD, MHA Isidore Professor and Chairman Department of Otolaryngology- Head and Neck Surgery Senior Associate Dean for Clinical Affairs The Icahn School
More informationIntroduction. Materials and methods Y-N XU 1,2, J-D WANG 1,2
1 di 5 11/04/2016 17:54 G Chir Vol. 31 - n. 5 - pp. 205-209 Maggio 2010 Y-N XU 1,2, J-D WANG 1,2 Introduction The World Health Organization (WHO) defined papillary thyroid microcarcinomas (PTMC) as tumors
More informationShifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer
DEBATE WJOES Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer Ashok R Shaha
More informationThe use of Radioactive Iodine (RAI) for Differentiated Thyroid Cancer
The use of Radioactive Iodine (RAI) for Differentiated Thyroid Cancer Wendy Sacks, M.D. Cedars Sinai Medical Center California Chapter Annual Meeting, AACE Nov 5, 2016 Increasing Incidence of Thyroid Cancer
More informationDifferentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment
ORIGINAL ARTICLE Differentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment Martínez MP, Lozano Bullrich MP, Rey M, Ridruejo MC, Bomarito MJ, Claus
More informationPersistent & Recurrent Differentiated Thyroid Cancer
Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of
More informationPediatric Thyroid Cancer Lung Metastases. Liora Lazar MD
Pediatric Thyroid Cancer Lung Metastases Liora Lazar MD Differentiated thyroid cancer (DTC) The 3rd most common solid tumor in childhood and adolescence Accounting for 1.5%-3% of all childhood cancers
More informationRadiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience
Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,
More informationStrategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer
Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer A rational approach to longterm follow-up based on dynamic risk assessment. World Congress on Thyroid
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationCurrent Issues in Thyroid Cancer Surgery in 2017
Current Issues in Thyroid Cancer Surgery in 2017 Dr. David Goldstein MD Msc FRCSC FACS Associate Professor, Department Otolaryngology Head & Neck Surgery, U of T Department of Surgical Oncology, Princess
More informationTreatment of Cervical Lymph Node Metastases Differentiated Thyroid Cancer
Treatment of Cervical Lymph Node Metastases Differentiated Thyroid Cancer Well Differentiated Thyroid Cancer Natural History and Prognosis EORTC AGES AMES MACIS QuickTime and a TIFF (LZW) decompressor
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More information- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer
Thyroid Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: 1. Lenvina is the first line therapy with powerful durable response and superior PFS in pts with RAI-refractory disease.
More informationClinical predictors of right upper paraesophageal lymph node metastasis from papillary thyroid carcinoma
Kim and Park World Journal of Surgical Oncology 2012, 10:164 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Clinical predictors of right upper paraesophageal lymph node metastasis from papillary
More informationInitial Lymph Node Dissection Increases Cure Rates in Patients with Medullary Thyroid Cancer
Original Article Initial Lymph Node Dissection Increases Cure Rates in Patients with Medullary Thyroid Cancer David Yü Greenblatt, Diane Elson, 1 Eberhard Mack and Herbert Chen, Departments of Surgery
More informationORIGINAL ARTICLE. Tzu-Chieh Chao, MD, PhD; Jen-Der Lin, MD; Long-Bin Jeng, MD; Miin-Fu Chen, MD
ORIGINAL ARTICLE Thyroid Cancer With Concurrent Hyperthyroidism Tzu-Chieh Chao, MD, PhD; Jen-Der Lin, MD; Long-Bin Jeng, MD; Miin-Fu Chen, MD Objective: To study the clinical manifestation, outcome, and
More informationPreoperative Evaluation
Preoperative Evaluation Lateral compartment lymph nodes are easier to detect and are amenable to FNA Central compartment lymph nodes are much more difficult to detect and FNA (Tg washout testing is compromised)
More informationSuccess rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan
ORIGINAL ARTICLE Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan I. Hommel 1 *, G.F. Pieters 1, A.J.M. Rijnders 2, M.M. van Borren 3, H. de
More informationChildhood and Adolescent Thyroid Carcinoma
724 Childhood and Adolescent Thyroid Carcinoma Perry W. Grigsby, M.D. 1 Anat Gal-or, B.Sc. 1 Jeff M. Michalski, M.D. 2 Gerard M. Doherty, M.D. 2 1 Department of Radiation Oncology, Mallinckrodt Institute
More informationProphylactic Central Compartment Neck Dissection(CCND) for Papillary Thyroid Cancer: Con
Prophylactic Central Compartment Neck Dissection(CCND) for Papillary Thyroid Cancer: Con Christopher R. McHenry, M.D. Vice Chairman Department of Surgery MetroHealth Medical Center Professor of Surgery
More informationSignificance of micrometastases in the calculation of the lymph node ratio for papillary thyroid cancer
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 https://doi.org/10.4174/astr.2017.92.3.117 Annals of Surgical Treatment and Research Significance of micrometastases in the calculation of the lymph node
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationClinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients
Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide
More informationMulti-Organ Distant Metastases in Follicular Thyroid Cancer- Rare Case Report
Multi-Organ Distant Metastases in Follicular Thyroid Cancer- Rare Case Report Dr. Mohammed Raza 1, Dr. Sindhuri K 2, Dr. Dinesh Reddy Y 3 1 Professor, Department of Surgery, JSS University, Mysore, India
More informationI-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Advances in Medical and Surgical Management of Thyroid Cancer January 23-24, 2015 I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER 2015 Leonard Wartofsky,
More information저작권법에따른이용자의권리는위의내용에의하여영향을받지않습니다.
저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,
More informationE it. Treating Differentiated Thyroid Carcinoma: Where Do We Draw the Line?
E it I Treating Differentiated Thyroid Carcinoma: Where Do We Draw the Line? Spectrum ofbehavior.-the clinical behavior of well-differentiated-papillary and follicular-thyroidcarcinomahas become increasingly
More informationCase year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationNeck Dissection. Asst Professor Jeeve Kanagalingam MA (Cambridge), BM BCh (Oxford), MRCS (Eng), DLO, DOHNS, FRCS ORL-HNS (Eng), FAMS (ORL)
Neck Dissection Asst Professor Jeeve Kanagalingam MA (Cambridge), BM BCh (Oxford), MRCS (Eng), DLO, DOHNS, FRCS ORL-HNS (Eng), FAMS (ORL) History radical neck Henry Butlin proposed enbloc removal of upper
More informationCase 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationDisclosures Nodal Management in Differentiated Thyroid Carcinoma
Disclosures Nodal Management in Differentiated Thyroid Carcinoma Nothing to disclose Jonathan George, MD, MPH Assistant Professor UCSF Head and Neck Oncologic & Endocrine Surgery Objectives Overview Describe
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationB. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.
B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life. b. Deficiency of dietary iodine: - Is linked with a
More information